The respiratory care specialist shares perspective on issues faced by respiratory studies, and how to overcome such obstacles to get therapies to market.
The two companies will combine their digital health services to offer clinical trial participants an inhaler equipped with a sensor to analyze patient adherence.
England’s High Court throws out the claim that Sandoz’s inhaler product passed off the appearance of GSK’s rival through its use of the color purple in packaging.
Mylan’s recently FDA-approved Advair Diskus generic to be offered at 70% cost reduction to its reference drug, and 67% less than GSK’s generic version.
A real-world trial of GSK's Relvar has prompted the development of a ‘game-changing’ database linking and tracking tech according to North West e-Health.
GlaxoSmithKline has issued upbeat guidance despite a 12% fall in sales of its blockbuster asthma and COPD drug Advair, as new products enter the respiratory drug market.
GlaxoSmithKline (GSK) has suffered a blow in the advance of its top
selling pharma drug Advair after US regulators issued a not
approvable letter for an increased strength in the treatment of
chronic obstructive pulmonary disease.
The market's first nebulized form of formoterol fumarate for
chronic obstructive pulmonary disease (COPD) has been given the go
ahead by the US Food and Drug Administration (FDA).
Novartis has acquired a global license to a combination drug and
inhaler device for chronic obstructive pulmonary disease (COPD) in
one of the largest deals signed by the UK biotechnology sector,
reports Phil Taylor.
Researchers have identified a serine protease inhibitor as a novel
candidate susceptibility gene for chronic obstructive pulmonary
disease (COPD). The discovery has major implications, especially in
smokers, where the role of the...